Complications associated with upfront and repeat surgical tissue sampling present the need for minimally invasive platforms capable of molecular sub-classification and temporal monitoring of tumor response to therapy. Here, we describe our dPCR-based method for the detection of tumor somatic mutations in cell free DNA (cfDNA), readily available in patient biofluids. Although limited in the number of mutations that can be tested for in each assay, this method provides a high level of sensitivity and specificity. Monitoring of mutation abundance, as calculated by MAF, allows for the evaluation of tumor response to therapy, thereby providing a much-needed supplement to radiographic imaging.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3791/59721 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of Mobile Application Based System for Improving Population Based Cancer Screening by Community Health Workers.
Asian Pac J Cancer Prev
January 2025
Cachar Cancer Hospital and Research Center, NS Avenue, Meherpur, Silchar, Assam, India.
Objective: Cancer remains a leading cause of morbidity and mortality globally, with India experiencing a significant cancer burden. Effective population-based cancer screening is crucial for early detection and reduction of cancer-related deaths. This study aims to develop a mobile application-based Cancer Screening and Surveillance System (CSMS) to enhance the efficiency and effectiveness of population-based cancer screening by community health workers (CHWs).
View Article and Find Full Text PDFEmerging Research and Future Directions on Doxorubicin: A Snapshot.
Asian Pac J Cancer Prev
January 2025
All India Institute of Medical Sciences, Department of Biochemistry, Vijaypur, Jammu, India.
Doxorubicin, a widely used anthracycline antibiotic, has been a cornerstone in cancer chemotherapy since the 1960s. In addition to doxorubicin, anthracycline chemotherapy medications include daunorubicin, idarubicin, and epirubicin. For many years, doxorubicin has been the chemotherapy drug of choice for treating a broad variety of cancers.
View Article and Find Full Text PDFGlucose Metabolic Abnormalities and Their Interaction With Defective Phosphate Homeostasis in Tumor-induced Osteomalacia.
J Clin Endocrinol Metab
January 2025
Department of Endocrinology, Key Laboratory of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Dongcheng District, National Commission of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
Context: Phosphate homeostasis was compromised in tumor-induced osteomalacia (TIO) due to increased fibroblast growth factor 23 (FGF23) secretion. Nevertheless, the glucose metabolic profile in TIO patients has not been investigated.
Objectives: This work aimed to clarify the glucose metabolic profiles in TIO patients and explore their interaction with impaired phosphate homeostasis.
Risk factors, monitoring, and treatment strategies for early recurrence after rectal cancer surgery.
World J Gastrointest Surg
January 2025
Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China.
Early recurrence (ER) following surgery for rectal cancer is a significant factor impacting patient survival rates. Tsai identified age, preoperative neoadjuvant therapy, length of hospital stay, tumour location, and pathological stage as factors influencing the risk of ER. Postoperative monitoring for ER should encompass a thorough medical history review, physical examination, tumour marker testing, and imaging studies.
View Article and Find Full Text PDFEarly identification and multidisciplinary management of immune checkpoint inhibitors associated colitis can improve patient outcomes.
World J Gastrointest Surg
January 2025
Department of Gastrointestinal Oncology Surgery, The Affiliated Hospital of Qinghai University, The Affiliated Cancer Hospital of Qinghai University, Xining 810000, Qinghai Province, China.
Currently, the use of immune checkpoint inhibitors (ICIs) has shown notable clinical efficacy in treating various malignant tumors, significantly improving patient prognosis. However, while ICIs enhance the body's anti-tumor effects, they can also trigger immune-related adverse events (irAEs), with ICI-associated colitis being one of the more prevalent forms. This condition can disrupt treatment, necessitate drug discontinuation, and adversely affect therapeutic outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!